KIR⁺ CD8 T cells are terminally differentiated cells. (A) Staining for total inhibitory KIR (hereafter termed pan-KIR) made with 4 mAbs specific for KIR2DL1, KIR2DL3, KIR3DL1, and KIR3DL2 on CD8 T cells from 1 representative individual (top) and frequency of pan-KIR⁺ CD8 T cells (bottom; n = 44; median). (B) Staining for CD27, CD28, CD57, CD127, CD45RA, and CCR7 on pan-KIR⁻ and pan-KIR⁺ CD8 T cells from 1 representative individual. (C) Expression of CD27, CD28, CD45RA, CD57, CD127, and CCR7 on pan-KIR⁻ and pan-KIR⁺ CD8 T cells (n = 39, 44, 43, 44, 44, and 21, respectively; ***P < .001, paired Student t test; mean). (D) Distribution of pan-KIR⁺ and pan-KIR⁻ CD8 T cells for expression of CD45RA, CD57, CD27, CD28, CCR7, and CD127 as defined by a Boolean gating scheme (n = 19; ***P < .001, 1-way ANOVA with Bonferroni multiple comparison test; mean ± SEM). (E) Staining for pan-KIR on CD45RA⁻CD57⁻, CD45RA⁻CD57⁺, and CD45RA⁺CD57⁺ CD8 T cells from 1 representative individual. (F) Pan-KIR expression on CD45RA⁻CD57⁻, CD45RA⁻CD57⁺, CD45RA⁺CD57⁺, and total CD8 T cells (n = 43; ***P < .001, 1-way ANOVA with Bonferroni multiple comparison test; mean).